James J. Campbell has had an extensive career in immunology research. He is currently a Senior Director at ChemoCentryx, where he leads pre-clinical research teams investigating drug mechanisms of action. Previously, he was a Principal Investigator and Professor at Harvard Medical School, where he managed an immunology lab and published over 60 peer-reviewed papers. He has received many awards and honors for his research and expertise in T cell biology, chemokines, and skin and intestinal immunity.

1. James J. Campbell, PhD
2433 Downing Avenue 617-270-6760 (work cell)
San Jose, CA jimijocam@gmail.com
Professional Accomplishments
 Director of a multi-disciplinary pre-clinical research team responsible for assessing mechanism of action for
small molecules in in vivo models of diabetic nephropathy, ulcerative colitis, psoriasis, atopic dermatitis and
melanoma. Responsible for coordinating interactions between the chemistry, pharmacokinetics, clinical and
pre-clinical teams.
 Managed and directed a lab as the Principal Investigator of an NIH-funded Immunology research program
within the Harvard Medical School system.
 Sixty-five peer-reviewed publications including the top-tier journals Nature, Science, Blood and Journal of
Experimental Medicine.
 Plenary speaker at numerous national and international scientific meetings, including Keystone
Conferences, Gordon Conferences, International Congress of Immunology, Society for Investigative
Dermatology, invited speaker at numerous universities, medical centers and biotech companies, including
Johns Hopkins University, University of Pennsylvania, Kinki University (Japan), Free University of
Amsterdam (Netherlands), Weizmann Institute (Israel), Cleveland Clinic, Massachusetts General Hospital,
Abbott Bioresearch, Novartis Pharmaceuticals (UK).
 Extensive experience as a scientific mentor, training four postdoctoral fellows who went on to
successful academic and industrial careers, and supervising the doctoral projects of three Harvard
students through attainment of their PhD degrees. Participated in teaching Graduate and Medical
students in formal classes at Harvard Medical School and Free University of Amsterdam.
 Accepted to and completed the Harvard Medical School “Leadership Development for Physicians and
Scientists” Program.
Specific Lab Skills
Expertise in design and execution of in vivo models of T cell biology, including bone marrow transplant and
lymphocyte adoptive transfer.
8(+)-color flow cytometry, ex-vivo chemotaxis and cell adhesion assays, and affinity purification of
endothelial-expressed adhesion molecules.
Design, construction and stable transfection of leukocyte cell lines with expression vectors.
Employment History
2013-present: Senior Director of Innovative Biology, ChemoCentryx, Inc., Mountain View, CA.
 Director of the Innovative Biology team, responsible for elucidating mechanism of action for clinical
compounds in fine detail using in vivo models.
 Project leader for pre-clinical CCR2 program, working in concert with clinical team.
 Project leader for pre-clinical CCR4 program.
 Project leader for pre-clinical melanoma immuno-oncology program.
2006-2013: Principal Investigator/Assistant Professor of Dermatology/Pathology, Harvard Medical School and
Brigham & Women’s Hospital, Boston, MA.
 Twenty-two peer-reviewed publications.
 Competitive Renewal NIH R01 grant, new awards of an R03 grant and two R21 grants (all as PI).
 Supervised dissertation projects of 3 Harvard PhD students.
2000-2006: Principal Investigator/Assistant Professor of Pathology, Harvard Medical School and Boston
Children’s Hospital, Boston, MA
 Twenty-three peer-reviewed publications.
 Awarded NIH R01 research grant as PI, and as Co-PI of an NCI “Special Program in Research
Excellence (SPORE)” grant (PI = T.S. Kupper).
 Trained 3 postdocoral fellows who went on to successful academic and industrial careers.
1993-2000: Postdoctoral Fellowship, Stanford University School of Medicine.
 Eighteen peer-reviewed publications.
Awarded individual research funding from NIH (2 years) and Arthritis Foundation of America (3 years).
Education
1987-1992: PhD in Immunology, University of Pennsylvania School of Medicine.
1980-1984: BA in Biology University of Pennsylvania College of Arts and Sciences.

2. Selected Peer-Reviewed Publications (of 65, in chronological order)
3.
*
Berlin, C.,
*
Bargatze, R.F.,
*
Campbell, J.J., von Andrian, U.H., Szabo, M.C., Hasslen, S.R. Nelson,
R.D., Berg, E.L., Erlandsen, S.L. and Butcher, E.C. α4 integrins mediate lymphocyte attachment and
rolling under physiologic flow. Cell 1995;80:413-422. (*equal contributors)
5. Campbell, J.J., Qin, S., Bacon, K.B., Mackay, C.R., and Butcher, E.C. Biology of chemokine and
classical chemoattractant receptors: differential requirements for adhesion-triggering versus
chemotactic responses in lymphoid cells. J. Cell Biol. 1996;134:255-266.
10. Campbell, J.J., Hedrick, J., Zlotnik, A., Siani, M.A., Thompson, D.A., and Butcher, E.C. Chemokines
and the arrest of lymphocytes rolling under flow conditions. Science 1998;279:381-384.
12. Campbell, J.J., Bowman, E.P., Murphy, K., Youngman, K.R., Siani, M.A., Thompson, D.A., Wu,
L.,Zlotnik, A., and Butcher, E.C. 6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine
expressed by high endothelium, is an agonist for the MIP-3β receptor CCR7. J. Cell Biol.
1998;141:1053-1059.
15. Campbell, J.J., Pan, J. and Butcher, E.C. Cutting Edge: Developmental Switches in Chemokine
Responses During T Cell Maturation. J. Immunol. 1999;163:2353-2357.
16. Campbell, J.J., Haraldsen, G., Pan, J., Rottman, J., Qin, S., Ponath, P., Andrew, D.P., Warnke, R.,
Ruffing, N., Kassam, N., Wu, L. and Butcher, E.C. The Chemokine Receptor CCR4 in Vascular
Recognition by Cutaneous but Not Intestinal Memory T Cells. Nature 1999;400:776-781.
20.
*
Kunkel E. J.,
*
Campbell, J.J., Haraldsen, G., Pan, J., Boisvert, J., Roberts, A. I., Ebert, E. C., Vierra, M.
A., Goodman S.B., Genovese, M.C., Wardlaw, A.J., Greenberg, H.B., Parker, C.M., Butcher, E.C.,
Andrew, D.P., and Agace, W.W.. Lymphocyte CCR9 and Epithelial TECK Expression Distinguish the
Small Intestinal Immune Compartment: Epithelial Expression of Tissue-Specific Chemokines as an
Organizing Principle in Regional Immunity. J. Exp. Med. 2000;192:761-767. (*equal contributors)
23. Campbell, J.J., Murphy, K.E., Kunkel E.J., Brightling, C.E., Soler, D., Shen, Z., Boisvert, J., Greenberg,
H.B., Vierra, M.A., Goodman, S.B., Genovese, M.C., Wardlaw, A.J., Butcher, E.C. and Wu, L. CCR7
Expression and Memory T Cell Diversity in Man. J. Immunol. 2001;166:877.
24. Campbell, J.J., Brightling, C.E., Symon, F.A., Qin, S., Murphy, K.E., Hodge, M.R., Andrew, D.P., Wu,
L., Butcher, E.C. and Wardlaw, A.J. Expression of Chemokine Receptors by Lung T Cells from Normal
and Asthmatic Subjects. J. Immunol. 2001;166:2842-2848.
26. Campbell, J.J., Qin, S., Unutmaz, D., Soler, D., Murphy, K.E., Hodge, M.R., Wu, L. and Butcher, E.C.
Unique Subpopulations of CD56(+) NK and NK-T Peripheral Blood Lymphocytes Identified by
Chemokine Receptor Expression Repertoire. J. Immunol. 2001;166:6477-6482.
29. Kunkel, E.J., Boisvert, J., Murphy, K., Vierra, M.A., Genovese, M.C., Wardlaw, A.J., Greenberg, H.J.,
Hodge, M.R.,Wu, L., Butcher, E.C. and Campbell, J.J. Expression of the Chemokine Receptors CCR4,
CCR5, and CXCR3 by Human Tissue-Infiltrating Lymphocytes. Am. J. Pathol. 2002;160:347-355.
33. Soler, D., Humphreys, T.L., Spinola, S.M., Campbell, J.J. CCR4 vs. CCR10 in Human Cutaneous Th
Lymphocyte Trafficking. Blood 2003;101:1677-1682.
37. Kivisakk, P., Mahad, D.J, Trebst, C., Tucky, B., Wu, L., Baekkevold, E.S., Lassmann, H., Campbell,
J.J., Ransohoff, R.M. Human Cerebrospinal Fluid CD4+
T-Cells: Evidence for Trafficking through
Choroid Plexus and Meninges via P-Selectin. Proc. Nat. Acad. Sci. USA. 2003; 100:8389-8394.
38. Baekkevold, E.S., Wurbel, M.A., Kivisakk, P., Wain, C., Power, C.A., Haraldsen, G., Campbell, J.J. A
Role for CCR4 in Development of Mature Circulating Cutaneous T Helper Memory Cell Populations. J.
Exp. Med. 2005; 201;1045-1051.
40. Wurbel, M.A., Malissen, B., Campbell, J.J. Complex Regulation of CCR9 at Multiple Discrete Stages of
T Cell Development. Eur. J. Immunol. 2006; 36:73-81.
43. Campbell, J.J., O’Connell, D.J., Wurbel, M.A. Cutting Edge: Chemokine Receptor CCR4 Is
Necessary For Antigen-Driven Cutaneous Accumulation of CD4 T Cells Under Physiological
Conditions. J. Immunol. 2007; 178:3358-3362.
45. Wurbel, M.A., Malissen, M., Guy-Grand, D., Malissen, B., Campbell, J.J. Impaired Accumulation of
Antigen-Specific CD8 Lymphocytes in Chemokine CCL25-Deficient Intestinal Epithelium and Lamina
Propria. J. Immunol. 2007; 178:7598-7606.
49. Campbell, J.J., Clark, R.A., Watanabe, R., Kupper, T.S. Sézary Syndrome and MF Arise from Distinct
T Cell Subsets: A Biologic Rationale for Their Distinct Clinical Behaviors. Blood 2010; 116:767-771.
56. Tubo, N.J., McLachlan, J.B., Campbell, J.J. Chemokine Requirements for Epidermal T Cell Trafficking.
Am. J. Pathol. 2011; 178:2496-2503.
61. Vander Lugt, B., Tubo, N.J., Nizza, S.T., Bose, M., Malissen, B., Fuhlbrigge, R.C., Kupper, T.S.
Campbell, J.J. CCR7 Plays No Appreciable Role In Trafficking of Central Memory CD4 T Cells to
Lymph Nodes. J. Immunol. 2013; 191:3119-27.